| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_dc3e06b96940b1f4271dccf2df2fa842 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D455-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-12 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D498-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4709 |
| filingDate |
2005-07-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2007-06-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d8ea1ff79febef5336ec05add8ef5947
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_252a9af9cdc8479c104ff92499e487a0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7567d3b800489fcb26ddbf79fe5e9020
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e0579b63efca695fce6a3c5538de5e06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_06def631bb47a935f2b84a8e8b430d72
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_997aeaa23f875d0f53df749c49b96f49
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_488fb708c8526e6b69714a8915186aa6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b312413eed478106e48c3b992730b21d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a294b776c761727306a26ae641991018
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c8ec1827bf99c0df67c73bb141f94504 |
| publicationDate |
2007-06-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-7226931-B2 |
| titleOfInvention |
(R/S) rifamycin derivatives, their preparations and pharmaceutical compositions |
| abstract |
Rifamycin derivatives having the following structure of general formula I (both hydroquinone and corresponding quinone (C 1 -C 4 ) forms): n nor its salts, hydrates or prodrugs thereof; wherein a preferred R 1 comprises hydrogen or acetyl and a prefered R 2 comprises hydrogen, methyl or other lower alkyls; wherein asterik (*) denotes the carbon bearing the chiral center, wherein absolute configuration is assigned as R or S. Methods of preparation of the aforementioned rifamycin derivatives are also described. The compounds exhibit antimicrobial activities, including activities against drug-resistant microorganisms. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2018353489-A1 |
| priorityDate |
2004-07-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |